Drawing for RESOLUTION

USPTO serial 90130276

RESOLUTION

Reviewed by CopyMark Law Group

Reg. 6770463Status 700Registered
Filing date
Status date
Registration date
Jun 28, 2022
Examiner
MUNN LEWIS, LAKEISHA S
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with RESOLUTION?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Rebecca Liebowitz

Rebecca Liebowitz VENABLE LLPP.O. BOX 34385WASHINGTON, DC 20043UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
001Cells for scientific purposes; molecular biology research tools in the nature of biological, chemical and biochemical reagents for research use; biological preparations for cell therapyACTIVE—
005Pharmaceutical preparations for the treatment of hematologic diseases, immune response disorders, neurological disorders, respiratory diseases, ophthalmological conditions, metabolic diseases, genetic conditions, cancer, infectious diseases and cardiovascular diseases; medical and veterinary preparations for therapeutic purposes for the treatment of hematologic diseases, immune response disorders, neurological disorders, respiratory diseases, ophthalmological conditions, metabolic diseases, genetic conditions, cancer, infectious diseases and cardiovascular diseases; cells for medical or veterinary use; pharmaceutical and biopharmaceutical preparations for modifying human or animal cells for medical or therapeutic purposes; pharmaceutical and biopharmaceutical preparations of cells from humans or animals which have been adapted for medical or therapeutic purposesACTIVE—
040Treatment and processing of biological materials; custom manufacture of therapeutic drugs, namely, custom manufacture of cells and cell therapiesACTIVE—
042Scientific and technological services and research and design relating thereto, namely, scientific research in the field of in the fields of haematology, immunology, neurology, respiratory diseases, ophthalmology, metabolic conditions, genetic conditions, oncology, immuno-oncology, infectious diseases and cardiovascular diseases; industrial research services, in the field of cell therapies and gene therapies; chemical and biological analysis and research services; scientific research in human and animal cell therapy; scientific research into preparations for manipulating and adapting human and animal cells; design and development of new products for others; scientific laboratory services, namely, manipulation of human and animal cells for therapeutic purposes ; advisory and consultancy relating to all the aforesaid servicesACTIVE—
044Medical and veterinary research services including the manipulation of biological reagents to be used for medical or therapeutic purposes; medical and veterinary research services including the manipulation of cells within a laboratory or research facility to enable the cells to be used for medical or therapeutic purposes; veterinary services; medical services in the nature of extraction of human and animal cells from patients; medical services, namely, reinsertion of cells into human and animal patients; providing advice and consultancy in the field of medical and veterinary therapiesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jun 28, 2022NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Jun 28, 2022R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Apr 12, 2022NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Apr 12, 2022PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Mar 23, 2022NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Mar 8, 2022CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Feb 7, 2022TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Feb 7, 2022CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Feb 2, 2022ALIEASSIGNED TO LIE—
Jan 26, 2022TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jul 27, 2021GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 27, 2021GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 27, 2021CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 24, 2021TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jun 24, 2021CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jun 24, 2021ALIEASSIGNED TO LIE—
Apr 14, 2021TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Dec 21, 2020GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 21, 2020GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 21, 2020CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 17, 2020DOCKASSIGNED TO EXAMINER—
Sep 24, 2020NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 25, 2020NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance